A phase I and a phase II study with navitoclax, a selective inhibitor of Bcl-2 and Bcl-x, showed limited activity in advanced and recurrent SCLC with a high rate of serious thrombocytopenia [91, 92]. This evidence concerns the gene BCL2 and Thrombocytopenia.